History of Establishment

The Tochino Foundation was established in 2017 based on a personal donation from Dr. Yoshihiro Tochino who offered to support patients with triglyceride deposit cardiomyovasculopathy (TGCV), those with neutral lipid storage diseases, and related research activities. Our foundation supports these patients in Japan and overseas and triglyceride-related medical research and development. Moreover, the foundation makes our best effort to develop research deliverables and products and contribute to solve global health problem.
Dr. Tochino continued his researches at the Osaka University until 85 years old. He was a mentor for animal experiments and regulatory sciences of Ken-ichi Hirano, President, and Satoshi Yamaguchi, Executive Director, for this foundation.

Business Overview

*** Patient Support Activities ***

TGCV Patients Support

TGCV is a novel heart disease that causes heart failure and coronary artery disease due to the accumulation of triglycerides in cardiomyocytes and vascular smooth muscle cells (Hirano K, et al. N Engl J Med. 2008, J Atheroscler Thromb. 2009) (Orphanet OPRHA code: 565612). Long-chain fatty acids is a major energy source for the normal heart. However, it  cannot be used in heart of patients with TGCV, which causes TG accumulation and energy failure.

       *** Research and Development Activities ***

Triglycerides-related Research and Product Development

The Triglyceride Laboratory and Business, Inc., a subsidiary of the foundation, supports scientific activities of academia and is developing products with capric acid, which is known to be the major fatty acid synthesized in mammary epithelial cells.